HER 2 Negative ER/PR Positive with Bone Metastases - Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

The objective of this study is to assess efficacy and safety of radium 223 dichloride in subjects with human epidermal growth factor receptor 2 (HER2) negative hormone receptor positive breast cancer with bone metastases treated with exemestane and everolimus.

See detailed information including eligibility. 

 

6/2015
6/2019
NCT02258451
Cancer, Adult Breast Cancer
Accepting Participants
Interventional
2